Swiss newborn screening for severe T and B cell deficiency with a combined TREC/KREC assay - management recommendations.


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
15 Jun 2020
Historique:
entrez: 25 6 2020
pubmed: 25 6 2020
medline: 19 8 2021
Statut: epublish

Résumé

The recent introduction of newborn screening for severe primary T and B cell deficiencies in Switzerland allows rapid identification of patients with severe combined immunodeficiency (SCID). Outcomes for SCID are greatly improved by early diagnosis and treatment with allogeneic haematopoietic stem cell transplantation or, in selected cases, gene therapy. National centralised newborn screening is performed in Switzerland since January 2019 using a combined T cell receptor excision circles (TREC) / κ-deleting recombination excision circles (KREC) assay, also revealing infants with non-SCID severe T and B cell disorders, who are often diagnosed with a substantial delay. Here, we outline the screening procedure currently performed in Switzerland and give recommendations for diagnostic evaluations and precautionary measures against infection in children with abnormal screening test results.

Identifiants

pubmed: 32579701
doi: 10.4414/smw.2020.20254
pii: Swiss Med Wkly. 2020;150:w20254
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

w20254

Auteurs

Johannes Trück (J)

University Children's Hospital Zurich, Switzerland.

Seraina Prader (S)

University Children's Hospital Zurich, Switzerland.

Giancarlo Natalucci (G)

Department of Neonatology, University Hospital Zurich and University of Zurich, Switzerland.

Cornelia Hagmann (C)

University Children's Hospital Zurich, Switzerland.

Barbara Brotschi (B)

University Children's Hospital Zurich, Switzerland.

Janet Kelly (J)

University Children's Hospital Zurich, Switzerland.

Dirk Bassler (D)

Department of Neonatology, University Hospital Zurich and University of Zurich, Switzerland.

Katharina Steindl (K)

Institute of Medical Genetics, University of Zurich, Switzerland.

Anita Rauch (A)

Institute of Medical Genetics, University of Zurich, Switzerland.

Matthias Baumgartner (M)

University Children's Hospital Zurich, Switzerland.

Ralph Fingerhut (R)

University Children's Hospital Zurich, Switzerland.

Mathias Hauri-Hohl (M)

University Children's Hospital Zurich, Switzerland.

Tayfun Güngör (T)

University Children's Hospital Zurich, Switzerland.

Jana Pachlopnik Schmid (J)

University Children's Hospital Zurich, Switzerland.

Christoph Berger (C)

University Children's Hospital Zurich, Switzerland.

Janine Reichenbach (J)

University Children's Hospital Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH